Catheter ablation reduces ventricular tachycardia burden in patients with arrhythmogenic right ventricular cardiomyopathy: insights from a north-western French multicentre registry - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue EP-Europace Année : 2018

Catheter ablation reduces ventricular tachycardia burden in patients with arrhythmogenic right ventricular cardiomyopathy: insights from a north-western French multicentre registry

, , (1, 2) , , , , , , , , , , ,
1
2
Zouheir Souissi
  • Fonction : Auteur
Stephane Boule
  • Fonction : Auteur
Alexandre Doucy
  • Fonction : Auteur
Philippe Mabo
  • Fonction : Auteur
Dominique Pavin
  • Fonction : Auteur
Frederic Anselme
  • Fonction : Auteur
Nathanael Auquier
  • Fonction : Auteur
Sandro Ninni
  • Fonction : Auteur
Augustin Coisne
  • Fonction : Auteur
Francois Brigadeau
  • Fonction : Auteur
Valerie Deken-Delannoy
  • Fonction : Auteur
Didier Klug
  • Fonction : Auteur
Dominique Lacroix
  • Fonction : Auteur

Résumé

Aims Studies assessing radiofrequency ablation (RFA) of ventricular tachycardia (VT) in arrhythmogenic right ventricular cardiomyopathy (ARVC) report VT recurrences, but have not evaluated the impact of RFA on relevant clinical events during follow-up. We aimed to investigate relevant RFA outcomes in a multicentric registry. Methods and results This study included 49 patients with ARVC (46 with definite diagnosis, 3 with borderline diagnosis according to revised Task Force Criteria) who underwent 92 RFA procedures (83 endocardial, 9 combined endo-epicardial) between 1999-2015. Ventricular tachycardia recurrences and VT burden were assessed after each procedure or after the last RFA. Over a mean follow-up of 64651 months, VT-free survival was 37% at 1 year, 19% at 5 years, and 14% at 10 years. Ventricular tachycardia burden was significantly reduced after one procedure (23 vs. 11 VT episodes/year, P<0.01) and after the last RFA (14 vs. 2 VT episodes/year, P<0.01). Over a mean follow-up of 49652 months, clinical response after the last RFA (freedom from sudden cardiac death, VT requiring hospitalization, or heart transplantation) was 86% at 1 year, 69% at 5 years, and 60% at 10 years. Clinical response was associated with right ventricular dysfunction (RVD) and low numbers of mappable VT before the first RFA. Conclusion RFA was predominantly targeted at the endocardial surface. Ventricular tachycardia recurrences were common, but few ARVC patients experienced major clinical events during follow-up. Further studies should investigate the benefit of extensive substrate ablation combined with endo-epicardial strategies.

Dates et versions

hal-03572229 , version 1 (14-02-2022)

Identifiants

Citer

Zouheir Souissi, Stephane Boule, Jean-Sylvain Hermida, Alexandre Doucy, Philippe Mabo, et al.. Catheter ablation reduces ventricular tachycardia burden in patients with arrhythmogenic right ventricular cardiomyopathy: insights from a north-western French multicentre registry. EP-Europace, 2018, 20 (2), pp.362-369. ⟨10.1093/europace/euw332⟩. ⟨hal-03572229⟩

Collections

U-PICARDIE MP3CV
4 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook Twitter LinkedIn More